Dirk Thye, Quince Therapeutics CEO
April 11, 2023 07:34 AM EDT
People

Af­ter set­ting up poi­son pill, Quince Ther­a­peu­tics board gives flat-out re­jec­tion to un­so­licit­ed buy­er

Kyle LaHucik

Senior Reporter

In a terse state­ment Tues­day morn­ing, Quince Ther­a­peu­tics said its board “unan­i­mous­ly re­ject­ed” the un­so­licit­ed pro­pos­al from Echo Lake Cap­i­tal and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times